Pregnancy Outcomes Following Maternal and Paternal Exposure to Teriflunomide During Treatment for Relapsing–Remitting Multiple Sclerosis

Neurology and Therapy

Volumn 3, Issue 2, 2014, Pages 133-138

  Kieseier, Bernd C ^a   Benamor, Myriam ^b  

^a Department of Orthopedic Surgery   (Germany)

^b SANOFI   (France)

Author keywords

Clinical trials; Multiple sclerosis; Pregnancy; Teratogenicity; Teriflunomide

Indexed keywords

ACTIVATED CARBON; BETA INTERFERON; COLESTYRAMINE; PLACEBO; TERIFLUNOMIDE;

ARTICLE; BIRTH WEIGHT; CLINICAL TRIAL; COMPLIANCE (PHYSICAL); CONTRACEPTION; DATA BASE; DRUG ELIMINATION; DRUG EXPOSURE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ENVIRONMENTAL EXPOSURE; FEMALE; FETUS RISK; GESTATIONAL AGE; HUMAN; INDUCED ABORTION; LIVE BIRTH; MAJOR CLINICAL STUDY; MALE; MEDICAL PROCEDURES; MULTIPLE SCLEROSIS; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY MONITORING; PREGNANCY OUTCOME; RETROSPECTIVE STUDY; SPONTANEOUS ABORTION;

EID: 84977110506     PISSN: 21938253     EISSN: 21936536     Source Type: Journal    
DOI: 10.1007/s40120-014-0020-y     Document Type: Article

References (14)

1. Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol. 2013;260:1202–4.
2. Lorenzi AR, Ford HL. Multiple sclerosis and pregnancy. Postgrad Med J. 2002;78:460–4.
3. Cree BA. Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler J. 2013;19:835–43.
4. AUBAGIO prescribing information. Cambridge: Genzyme Corporation, a Sanofi company; 2012. Available from: http://products.sanofi.us/aubagio/aubagio.pdf. Accessed Aug 28, 2014.
5. AUBAGIO Summary of Product Characteristics. Paris: Sanofi-aventis groupe; 2013. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002514/WC500148682.pdf. Accessed Aug 28, 2014.
6. Garcia-Enguidanos A, Calle ME, Valero J, Luna S, Dominguez-Rojas V. Risk factors in miscarriage: a review. Eur J Obstet Gynecol Reprod Biol. 2002;102:111–9.
7. Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82:674–80.
8. ARAVA prescribing information. Bridgewater: Sanofi-aventis U.S. LLC; 2014. Available from: http://products.sanofi.us/arava/arava.html. Accessed Aug 28, 2014.
9. Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. Arthritis Rheum. 2010;62:1494–503.
10. Cassina M, Johnson DL, Robinson LK, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum. 2012;64:2085–94.
11. Organization of Teratology Information Specialists (OTIS). MotherToBaby. Available from: www.pregnancystudies.org. Accessed Oct 31, 2014.
12. O’Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365:1293–303.
13. Confavreux C, O’Connor P, Comi G, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:247–56.
14. Freedman MS. Teriflunomide in relapsing multiple sclerosis: therapeutic utility. Ther Adv Chronic Dis. 2013;4:192–205.